Clinical trial • Phase I/II • Haematology
tocilizumab for Acute myeloid leukaemia
Phase I/II trial of tocilizumab for Acute myeloid leukaemia. 12 participants.
Overview
- Trial Therapeutic Area
- Haematology
- Trial Disease
- Acute myeloid leukaemia
- Trial Stage
- Phase I/II
- Drug Modality
- Monoclonal antibody|Small molecule
Key dates
- Initial CTIS Submission Date
- 19-01-2026
- First CTIS Authorization Date
- 10-04-2026
Trial design
Phase I/II trial across 1 site in France.
- Single Multiple Or Escalation Dose Combined
- Yes
- Target Sample Size
- 12
Eligibility
Recruits 12 Vulnerable populations not selected; consent/assent handling not specified..
- Vulnerable Population
- Vulnerable populations not selected; consent/assent handling not specified.
Recruitment
- Planned Sample Size
- 12
- Recruitment Window Months
- 48
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 12
France
- Earliest CTIS Part Ii Submission Date
- 05-03-2026
- Latest Decision Or Authorization Date
- 10-04-2026
- Processing Time Days
- 36
- Number Of Sites
- 1
- Number Of Participants
- 12
Sites
- Site Name
- Centre Hospitalier Universitaire De Nantes
- Department Name
- Hematological
- Contact Person Name
- Pierre Peterlin
- Contact Person Email
- pierre.peterlin@chu-nantes.fr
- Number Of Participants
- 12
Sponsor
Primary sponsor
- Full Name
- Centre Hospitalier Universitaire De Nantes
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- France
Investigational products
- Investigational Product Name
- Tocilizumab
- Active Substance
- tocilizumab
- Modality
- Monoclonal antibody
- Investigational Product Name
- Venetoclax
- Active Substance
- venetoclax
- Modality
- Small molecule
- Investigational Product Name
- Azacitidine
- Active Substance
- azacitidine
- Modality
- Small molecule
- Combination Treatment
- Yes
Related trials
Other published trials that may interest you.
- Gilteritinib for Acute myeloid leukaemia
- VENETOCLAX for Acute myeloid leukaemia
- (S)-4,5-DIHYDRO-2-[2-HYDROXY-4-(3,6-DIOXAHEPTYLOXY)PHENYL]-4-METHYL-4-THIAZOLECARBOXYLIC ACID for Transfusion-dependent alpha thalassemia | Transfusion-dependent beta thalassemia | Low-risk myelodysplastic syndromes
- Luspatercept for Myelofibrosis | Anemia associated with myeloproliferative neoplasm-associated myelofibrosis
- GIVINOSTAT for Chronic myeloproliferative neoplasm